When Novo Nordisk announced in December that it would commence studies with oral semaglutide for treating Alzheimer's, the firm expected that this would happen in the course of the first half-year of 2021.
According to database clinicaltrials.gov, Novo Nordisk is now one step closer to starting this process. The firm has registered two studies for the disease, which are currently scheduled to start on May 18.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.